CONMED (CNMD) Stock Price, News & Analysis

Company Overview

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy. The Orthopedics segment offers arthroscopic shavers, burrs and handpieces, as well as joint repair and reconstruction implants. In its Visualization & Energy segment, CONMED provides endoscopic imaging systems, electrosurgical and radiofrequency generators, insufflators, ablation devices and related disposables. These technologies are designed to improve procedural efficiency, safety and patient outcomes.

With a presence in over 70 countries, CONMED sells products through direct sales forces as well as distributor partnerships. The company’s international footprint spans North America, Europe, Latin America, Asia Pacific and select emerging markets. CONMED works closely with healthcare facilities and surgical centers to deliver training, technical support and service solutions tailored to local regulatory requirements and clinical practices.

Leadership at CONMED includes President and Chief Executive Officer Jeffrey M. Dunn, whose tenure has focused on strategic growth through product innovation and targeted acquisitions. Over its history, the company has expanded both organically and via the integration of complementary businesses to broaden its capabilities in key procedural areas. CONMED remains committed to advancing minimally invasive surgical technologies and supporting clinicians worldwide.

Key Stats

• Today's Range: $32.11 to $32.92
• 50-Day Range: $32.02 to $39.74
• 52-Week Range: $31.84 to $56.63
• Volume: 1.23 million shs
• Average Volume: 537,652 shs
• Market Capitalization: $981.22 million
• P/E Ratio: 18.41
• Dividend Yield: N/A
• Price Target: $39.50
• Consensus Rating: Reduce

CONMED Stock Analysis - MarketRank™

CONMED scored higher than 65% of companies evaluated by MarketBeat, and ranked 260th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Reduce

Consensus Rating

CONMED has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no strong buy ratings, no buy ratings, 6 hold ratings, and 1 sell rating.

Upside Potential

CONMED has a consensus price target of $39.50, representing about 21.2% upside from its current price of $32.59.

Amount of Analyst Coverage

CONMED has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 10.27%

Earnings Growth

Earnings for CONMED are expected to grow by 10.27% in the coming year, from $4.38 to $4.83 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CONMED is 18.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of CONMED is 18.41, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.49.

Price to Earnings Growth Ratio

CONMED has a PEG Ratio of 1.60. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

CONMED has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.80% of the float of CONMED has been sold short.

Short Interest Ratio / Days to Cover

CONMED has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in CONMED has recently increased by 2.18%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.8 / 5
• Dividend Strength: N/A

Dividend Yield

CONMED does not currently pay a dividend.

Dividend Growth

CONMED does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, CONMED will have a dividend payout ratio of 12.42% next year. This indicates that CONMED will be able to sustain or increase its dividend.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: 0.25

News Sentiment

CONMED has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for CONMED this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for CNMD on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CONMED insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.28% of the stock of CONMED is held by insiders.

Percentage Held by Institutions

CONMED has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 4/29/2026
• Today: 6/20/2026
• Next Earnings (Estimated): 7/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED/DENTAL - SUPP
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:CNMD
• CIK: 816956
• Web: www.conmed.com
• Phone: (727) 392-6464
• Fax: 315-797-0321
• Employees: 3,900
• Year Founded: 1970

Price Target and Rating

• Average Price Target for CONMED: $39.50
• High Price Target: $40.00
• Low Price Target: $39.00
• Potential Upside/Downside: +21.2%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.77
• Trailing P/E Ratio: 18.41
• Forward P/E Ratio: 7.44
• P/E Growth: 1.6
• Net Income: $47.06 million
• Net Margins: 4.00%
• Pretax Margin: 5.97%
• Return on Equity: 13.84%
• Return on Assets: 6.05%

Debt

• Debt-to-Equity Ratio: 0.85
• Current Ratio: 2.29
• Quick Ratio: 1.04

Sales & Book Value

• Annual Sales: $1.37 billion
• Price / Sales: 0.72
• Cash Flow: $7.21 per share
• Price / Cash Flow: 4.52
• Book Value: $33.36 per share
• Price / Book: 0.98

Miscellaneous

• Outstanding Shares: 30,109,000
• Free Float: 30,025,000
• Market Cap: $981.22 million
• Optionable: Optionable
• Beta: 0.92